Matthew Ebia

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Andrew Eugene Hendifar · 4 shared papers, 2023–2025 · strength 0.95
   • Paper Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma. DOI 10.21037/jgo-23-12↗
   • Paper Evaluating the Effect of KRAS Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer. DOI 10.1200/po-24-00684↗
   • Paper Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from … DOI 10.1093/oncolo/oyaf007↗
2. Jun Gong · 3 shared papers, 2025 · strength 0.64
   • Paper Evaluating the Effect of KRAS Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer. DOI 10.1200/po-24-00684↗
   • Paper Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from … DOI 10.1093/oncolo/oyaf007↗
   • Paper Enhancing management of pancreatic cancer: impact of a same day multidisciplinary clinic on access to guideline-directe… DOI 10.1016/j.hpb.2025.07.012↗
3. Arsen Osipov · 3 shared papers, 2025 · strength 0.64
   • Paper Evaluating the Effect of KRAS Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer. DOI 10.1200/po-24-00684↗
   • Paper Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from … DOI 10.1093/oncolo/oyaf007↗
   • Paper Enhancing management of pancreatic cancer: impact of a same day multidisciplinary clinic on access to guideline-directe… DOI 10.1016/j.hpb.2025.07.012↗
4. Michael Jon Pishvaian · 2 shared papers, 2025 · strength 0.46
   • Paper Evaluating the Effect of KRAS Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer. DOI 10.1200/po-24-00684↗
   • Paper Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from … DOI 10.1093/oncolo/oyaf007↗
5. Srinivas Gaddam · 2 shared papers, 2025 · strength 0.44
   • Paper Evaluating the Effect of KRAS Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer. DOI 10.1200/po-24-00684↗
   • Paper Enhancing management of pancreatic cancer: impact of a same day multidisciplinary clinic on access to guideline-directe… DOI 10.1016/j.hpb.2025.07.012↗
6. Abrahm Levi · 2 shared papers, 2025 · strength 0.39
   • Paper Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from … DOI 10.1093/oncolo/oyaf007↗
   • Paper Enhancing management of pancreatic cancer: impact of a same day multidisciplinary clinic on access to guideline-directe… DOI 10.1016/j.hpb.2025.07.012↗
7. Megan Philippa Hitchins · 1 shared paper, 2023 · strength 0.31
   • Paper Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma. DOI 10.21037/jgo-23-12↗
8. Emanuel F. Petricoin · 1 shared paper, 2025 · strength 0.26
   • Paper Evaluating the Effect of KRAS Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer. DOI 10.1200/po-24-00684↗
9. Rachna T. Shroff · 1 shared paper, 2025 · strength 0.20
   • Paper Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from … DOI 10.1093/oncolo/oyaf007↗
10. Emanuel F. Petricoin · 1 shared paper, 2025 · strength 0.20
    • Paper Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from … DOI 10.1093/oncolo/oyaf007↗
11. Jennifer W. Chuy · 1 shared paper, 2025 · strength 0.20
    • Paper Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from … DOI 10.1093/oncolo/oyaf007↗
12. Raymond Couric Wadlow · 1 shared paper, 2025 · strength 0.20
    • Paper Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from … DOI 10.1093/oncolo/oyaf007↗
13. Lei Zheng · 1 shared paper, 2025 · strength 0.20
    • Paper Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from … DOI 10.1093/oncolo/oyaf007↗
14. Gillian K. Gresham · 1 shared paper, 2025 · strength 0.20
    • Paper Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from … DOI 10.1093/oncolo/oyaf007↗
15. Lynn McCormick Matrisian · 1 shared paper, 2025 · strength 0.20
    • Paper Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from … DOI 10.1093/oncolo/oyaf007↗
16. Simon K. Lo · 1 shared paper, 2025 · strength 0.19
    • Paper Enhancing management of pancreatic cancer: impact of a same day multidisciplinary clinic on access to guideline-directe… DOI 10.1016/j.hpb.2025.07.012↗
17. Brent K. Larson · 1 shared paper, 2025 · strength 0.19
    • Paper Enhancing management of pancreatic cancer: impact of a same day multidisciplinary clinic on access to guideline-directe… DOI 10.1016/j.hpb.2025.07.012↗
18. Alexandra Gangi · 1 shared paper, 2025 · strength 0.19
    • Paper Enhancing management of pancreatic cancer: impact of a same day multidisciplinary clinic on access to guideline-directe… DOI 10.1016/j.hpb.2025.07.012↗
19. Mitchell R. Kamrava · 1 shared paper, 2025 · strength 0.19
    • Paper Enhancing management of pancreatic cancer: impact of a same day multidisciplinary clinic on access to guideline-directe… DOI 10.1016/j.hpb.2025.07.012↗
20. Nicholas N. Nissen · 1 shared paper, 2025 · strength 0.19
    • Paper Enhancing management of pancreatic cancer: impact of a same day multidisciplinary clinic on access to guideline-directe… DOI 10.1016/j.hpb.2025.07.012↗
21. Cristina Rosa Ferrone · 1 shared paper, 2025 · strength 0.19
    • Paper Enhancing management of pancreatic cancer: impact of a same day multidisciplinary clinic on access to guideline-directe… DOI 10.1016/j.hpb.2025.07.012↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.